Terns Pharmaceuticals Prepares Investors for Key TERN-701 Data
Terns Pharmaceuticals (Nasdaq: TERN) is gearing up for a major milestone. Ahead of Phase 1 data expected in Q4 2025, the company will host an investor educational webinar to highlight its lead oncology candidate, TERN-701, and its potential best-in-class profile in chronic myeloid leukemia (CML).
Why This Matters
CML has long been managed by tyrosine kinase inhibitors (TKIs). Yet resistance, intolerance, and long-term side effects leave patients in need of better options.
This is where TERN-701 steps in—a next-generation, oral, allosteric BCR-ABL inhibitor designed to target the ABL myristoyl pocket.
Webinar Details
- Topic: TERN-701 — Investor Educational Webinar
- Date: September 3, 2025
- Time: 4:30 p.m. ET
- Access: Register on Terns Investor Relations site
- Replay: Available on the website after the event
The session will be led by Terns leadership:
- Amy Burroughs – Chief Executive Officer
- Emil Kuriakose, M.D. – Chief Medical Officer
- Scott Harris – Chief Development Officer
About the CARDINAL Trial
Study design: Phase 1, multi-center, global trial (NCT06163430)
- Stage 1: Dose escalation – Completed Jan 2025 with no dose-limiting toxicities up to 500 mg QD.
- Stage 2: Dose expansion – Launched April 2025 with patients randomized to 320 mg or 500 mg QD (up to 40 patients per arm).
What’s next: Data readout in Q4 2025 will include 6-month major molecular response (MMR) rates, safety, and tolerability.
Early Signs Are Promising
- Compelling molecular responses were observed even at the lowest dose.
- Heavily pre-treated patients showed meaningful reductions in BCR-ABL transcript levels.
- Clean safety profile so far: no dose-limiting toxicities, no treatment-related discontinuations, no dose reductions.
If these trends hold, TERN-701 could offer a new standard of care in an evolving CML treatment landscape.
About Terns Pharmaceuticals
Terns is a clinical-stage biotech advancing small-molecule therapies for oncology and obesity.
Pipeline highlights:
- TERN-701 – Allosteric BCR-ABL inhibitor (CML)
- GLP-1 receptor agonist – Obesity
- THR-β agonist – Metabolic diseases
- Preclinical GIPR modulator program – With a GIPR antagonist in nomination
Takeaway: TERN-701 isn’t just another CML therapy in development. If the Phase 1 data delivers, Terns could position itself as a serious player in next-generation cancer therapeutics.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!